We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Bioanalysis
BioTechniques
Future Drug Discovery
Future Medicinal Chemistry
Future Science OA
International Journal of Pharmacokinetics
Pharmaceutical Patent Analyst
Therapeutic Delivery
News & Analysis

Conference Report: Bioanalytical Procedures and Regulation: Towards Global Harmonization

    Howard M Hill

    Huntingdon Life Sciences, Woolley Road, Alconbury, Cambridgeshire, PE28 4HS, UK.

    Search for more papers by this author

    Email the corresponding author at hillh@ukorg.huntingdon.com

    Published Online:21 Feb 2011https://doi.org/10.4155/bio.10.211

    Abstract

    The session on Bioanalytical Procedures and Regulation Towards Global Harmonization at the American Association of Pharmaceutical Scientists – Pharmaceutical Sciences World Congress meeting was organized by Mark Arnold (Bristol-Myers Squibb, NY, USA) who co-chaired with Brian Booth (US FDA) and Howard Hill (Huntingdon Life Sciences, Cambridgeshire, UK). The session continued the ongoing discussions and debate around harmonization of bioanalytical regulations in today’s globalized pharmaceutical development arena.

    Bibliography

    • 1  van Amsterdam P, Arnold M, Bansal S et al. Building the global bioanalysis consortium – working towards a functional globally acceptable and harmonized guideline on bioanalytical method validation. Bioanalysis2(11),1801–1803 (2010).
      CASGoogle Scholar
    • 2  US FDA. Guidance for industry: bioanalytical method validation. US Department of Health and Human Services. US FDA CDER, MD, USA (2001).
      Google Scholar
    • 3  European Medicines Agency. Concept paper/recommendations on the need for a (CHMP) guideline on the validation of bioanalytical methods. EMEA/CHMP/EWP/531305/2008 (2008).
      Google Scholar
    • 4  European Medicines Agency. Draft guideline on the validation of bioanalytical methods. EMA, Committee for Proprietary Medicinal Products (Committee for Medicinal Products for Human use), London, UK (2009).
      Google Scholar
    • 5  Smith G. Bioanalytical method validation: notable points in the 2009 draft EMA guideline and differences with the 2001 FDA guidance. Bioanalysis2(5),929–935 (2010).
      CASGoogle Scholar
    • 6  van Amsterdam P, Lausecker B, Luedtke S, Timmerman P, Brudny-Kloeppel M. Towards harmonized regulations for bioanalysis: moving forward! Bioanalysis2(2),689–691 (2010).
      CASGoogle Scholar
    • 7  Timmerman P, Lowes S, Fast DM, Garofolo F. Request for global harmonization of the guidance for bioanalytical method validation and sample analysis. Bioanalysis2(4),683 (2010).
      CASGoogle Scholar
    • 8  Savoie N, Garofolo F, van Amsterdam P et al. White Paper on recent issues in regulated bioanalysis and global harmonization of bioanalytical guidance. Bioanalysis2(12),1945–1960 (2010).
      CASGoogle Scholar
    • 9  Zhong D, Tang D. Regulated bioanalysis and the desire for harmonized regulations in China. Bioanalysis2(12),1913–1919 (2010).
      Google Scholar
    • 10  Tudan C, Rogenthien S, Jones A. SQA opinion paper on global harmonization of the bioanalytical method validation guidances. Bioanalysis2(12),1921–1925 (2010).
      CASGoogle Scholar
    • 101  Bioanalysis Zone. www.bioanalysis-zone.com
      Google Scholar